Moreover, although GLI1 suppression is dose- and exposure-dependent, a reduction of GLI1 expression did not always correlate with tumor response in the phase 1 efficacy and safety study for sonidegib, most likely due to limited sample size, indicating resistance may develop despite GLI1 inhibition [10]. This evidence concerns the gene GLI1 and neoplasm.